07 August 2014

Baxter Opens Biologics Facility in Singapore

Singapore - 7 August 2014 - Baxter International Inc. today formally opened its first advanced recombinant biologic facility in Singapore, and announced expansion plans for a new recombinant protein processing suite. In total, the establishment of the facility and new investment will have created 450 biopharmaceutical jobs by 2015 in Singapore.

"As a long-standing, established leader in the global hemophilia community, Baxter has focused efforts on improving standards of care for people with hemophilia," said Ludwig Hantson, Ph.D., president of Baxter BioScience. "The opening of the Singapore facility reinforces our continued commitment to expanding access to advanced, high quality treatments for patients around the world."

"Baxter's expansion of its biologics footprint in Singapore reinforces our position as a leading biologics hub. This facility will support Baxter's growth in the global market and Singapore celebrates its opening. Singapore Economic Development Board (EDB) will continue to invest in talent development, supporting infrastructure and new technologies to support the biologics sector," said Mr. Yeoh Keat Chuan, managing director at the Singapore Economic Development Board. 

The Singapore facility received regulatory approval from the European Medicines Agency in January 2014 for the production of ADVATE2. This allows the facility to process and supply ADVATE to the European Union, Iceland and Norway. The biologics facility in Singapore currently employs more than 400 production staff and expects to reach 450 by 2015 to support the second processing suite. The facility is the third location in the world supporting ADVATE processing, making this the only recombinant factor VIII treatment processed at three separate sites and providing unprecedented security of a triple-source capability.

Source: Baxter